Key Highlights

  • The market data has Fulgent Genetics (NASDAQ:FLGT) at USD 22.33 on Friday, November 6, 2026, a 19.64% advance that followed third-quarter results released after the November 5 session.
  • Sales advanced roughly 8%, reaching USD 90.4 million against USD 84.1 million in the comparison period, yet the GAAP loss deepened to USD 13.2 million, equal to USD 0.48 a share.
  • Revenue guidance for full-year 2026 stays at USD 330 million to USD 340 million, and the non-GAAP net loss expectation now sits between USD 46 million and USD 50 million.
  • Cash and securities reached USD 652.4 million at September 30, 2026, and Buybacks this year have consumed USD 64.1 million so far.

Revenue Growth and a Better Loss Outlook Versus a Wider Loss

Results for the third quarter of 2026 came out on November 5, 2026, once regular trading had ended, and the market data puts the stock at USD 22.33 after a 19.64% gain on the next day. Top-line Revenue hit USD 90.4 million, roughly 8% above the USD 84.1 million comparison. On a GAAP basis the loss came to USD 13.2 million, while the year-earlier loss appears only as USD 0.21 per share in the material reviewed, so a dollar comparison is not available. Non-GAAP results show a net loss of USD 2.4 million, or USD 0.09 per share, compared with USD 4.5 million of non-GAAP income in the comparison period. Adjusted EBITDA swung to a USD 7.5 million loss from a USD 0.7 million profit. On its own, the headline loss does not account for the advance.

Collection Gains and Tighter Costs Shape the Loss Outlook

Fulgent runs a laboratory services arm alongside a therapeutic development unit. The CFO credited the quarter to better collection rates and progress on a billing system problem, and management pointed to disciplined expense control for the improved non-GAAP loss forecast. Full-year revenue guidance was left unchanged at USD 330 million to USD 340 million, while the non-GAAP net loss is now expected in a USD 46 million to USD 50 million band. Cash and securities at year-end are projected near USD 630 million, assuming no further buybacks in the near term. The company cited a reduction of 4.1 million shares from repurchases this year. The likeliest reading is that cash and cost matter more to the stock than growth, although the company has made no statement on the price move. Lower weighted share counts from retired shares also support per-share results.

Thinner Gross Margin and Cash Cushion Set the Risk Balance

Margins went the other way. Gross margin slipped to 35.3% from 42.2%, cost of revenue climbed to USD 58.5 million from USD 48.6 million, and selling and Marketing spending went up from USD 11.6 million to USD 15.6 million. On an operating basis under GAAP, the company lost USD 22.5 million. Liquidity of USD 652.4 million breaks down into USD 86.8 million held as cash and USD 565.5 million in marketable securities, which gives room to absorb losses. Downside cases include renewed collection slippage, pressure on reimbursement, and a quote that jumped 19.64% in a single session, a jump that could give back ground if upcoming margins disappoint.

Where Things Stand

The gain seems tied more to the cash position and the better loss forecast than to a clean Earnings beat. Measured on the market data, Fulgent Genetics (NASDAQ:FLGT) stands at USD 22.33 after a 19.64% advance, with revenue up about 8%, the loss forecast narrowed and USD 652.4 million in liquid holdings, though the GAAP loss deepened and gross margin dropped to 35.3%. This interpretation is inferred from the release rather than declared by management. Upcoming checks include fourth-quarter gross margin, whether collection rates keep improving, how the billing system problem gets fixed and whether roughly USD 21 million of therapeutic development spending this year yields program progress.